{"id":"oxycodone-naloxone-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxycodone binds to mu-opioid receptors in the central nervous system to produce pain relief and is a Schedule II controlled substance. Naloxone is a competitive opioid antagonist added in a fixed ratio; when the tablet is taken intact orally, naloxone is poorly absorbed and has minimal effect, but if the tablet is crushed or dissolved for injection or inhalation, naloxone becomes bioavailable and blocks opioid effects, thereby deterring abuse.","oneSentence":"Oxycodone acts as a mu-opioid receptor agonist to provide analgesia, while naloxone is an opioid antagonist included to reduce abuse potential by blocking euphoric effects if the tablet is tampered with.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:35:31.668Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe chronic pain in opioid-tolerant patients"},{"name":"Abuse-deterrent formulation for reduced misuse risk"}]},"trialDetails":[{"nctId":"NCT06897917","phase":"PHASE4","title":"Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-04","conditions":"Opioid-Induced Constipation, Pain Cancer","enrollment":203},{"nctId":"NCT02454712","phase":"PHASE1","title":"Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2016-11-16","conditions":"Healthy","enrollment":64},{"nctId":"NCT05043766","phase":"PHASE1","title":"Evaluation of Oral PF614 Relative to OxyContin (PF614-102)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2021-09-08","conditions":"Healthy Volunteers","enrollment":84},{"nctId":"NCT05389813","phase":"PHASE2, PHASE3","title":"Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia","status":"UNKNOWN","sponsor":"An-Najah National University","startDate":"2021-08-15","conditions":"Anesthesia","enrollment":150},{"nctId":"NCT02571881","phase":"PHASE4","title":"Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section","status":"UNKNOWN","sponsor":"Kuopio University Hospital","startDate":"2012-10","conditions":"Constipation, Pain, Postoperative","enrollment":57},{"nctId":"NCT00929253","phase":"NA","title":"Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II)","status":"COMPLETED","sponsor":"Virginia Polytechnic Institute and State University","startDate":"2007-09","conditions":"Opiate Addiction","enrollment":170},{"nctId":"NCT03740243","phase":"PHASE4","title":"Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology","status":"WITHDRAWN","sponsor":"Stony Brook University","startDate":"2018-11-30","conditions":"Opioid-use Disorder","enrollment":""},{"nctId":"NCT01885182","phase":"PHASE3","title":"Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain","status":"COMPLETED","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2013-06-01","conditions":"Cancer, Pain","enrollment":232},{"nctId":"NCT02880475","phase":"PHASE1","title":"OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients","status":"COMPLETED","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2014-06-01","conditions":"Chronic Pain","enrollment":30},{"nctId":"NCT00513656","phase":"PHASE2","title":"A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2007-09","conditions":"Cancer, Pain, Constipation","enrollment":230},{"nctId":"NCT01197261","phase":"PHASE2","title":"OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2010-09","conditions":"Interstitial Cystitis, Painful Bladder Syndrome, Pain","enrollment":120},{"nctId":"NCT00412100","phase":"PHASE3","title":"Oxycodone-naloxone Prolonged Release Tablets in Relieving Opioid-related Constipation","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2006-04","conditions":"Pain","enrollment":""},{"nctId":"NCT01971632","phase":"PHASE3","title":"A Randomised, Double Blind, Placebo and Active Controlled, Double Dummy,Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Nonmalignant Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2005-01","conditions":"Subjects With Moderate to Severe, Chronic Nonmalignant Pain","enrollment":463},{"nctId":"NCT01438567","phase":"PHASE3","title":"A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2011-09","conditions":"Pain, Constipation","enrollment":270},{"nctId":"NCT00412152","phase":"PHASE3","title":"Oxycodone-naloxone in Relieving Opioid-related Constipation","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2006-01","conditions":"Pain","enrollment":""},{"nctId":"NCT01112644","phase":"PHASE3","title":"Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2010-04","conditions":"Moderate to Severe Idiopathic RLS With Daytime Symptoms","enrollment":205},{"nctId":"NCT00902837","phase":"PHASE3","title":"OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2009-05","conditions":"Chronic Osteoarthritis","enrollment":181},{"nctId":"NCT01918098","phase":"PHASE3","title":"Targin for Non-cancer Pain","status":"COMPLETED","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2013-09-01","conditions":"Non Cancer Pain","enrollment":230},{"nctId":"NCT00679614","phase":"PHASE3","title":"Effect of Combined Use of Naloxone and Tramacet on Postop Analgesia in Elderly Patients Having Joint Replacement Surgery","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2007-12-17","conditions":"Hip Arthroplasty, Knee Arthroplasty, Spinal Anesthesia","enrollment":45},{"nctId":"NCT02032927","phase":"PHASE4","title":"Treatment of Chronic Pain From Osteoarthritis","status":"WITHDRAWN","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2013-06","conditions":"Chronic Pain","enrollment":""},{"nctId":"NCT02321397","phase":"PHASE2, PHASE3","title":"To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2014-11","conditions":"Malignant Pain, Non-malignant Pain","enrollment":155},{"nctId":"NCT01719757","phase":"PHASE4","title":"PROspective Non-interventional Open laBEl Trial for TARGIN in Korean Patients With Cancer Pain","status":"COMPLETED","sponsor":"Mundipharma Korea Ltd","startDate":"2012-07","conditions":"Cancer","enrollment":359},{"nctId":"NCT02391571","phase":"PHASE3","title":"A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects","status":"COMPLETED","sponsor":"Elite Laboratories, Inc","startDate":"2015-02","conditions":"Withdrawal Symptoms","enrollment":26},{"nctId":"NCT00734461","phase":"PHASE2","title":"Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2007-08","conditions":"Opioid-Related Disorders","enrollment":14},{"nctId":"NCT01915147","phase":"PHASE2","title":"A Study to Explore the Influence of Two Opioid Pain Medications on Bacterial Composition in the Gut and Other Gastrointestinal Aspects","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2013-07","conditions":"Severe Chronic Pain","enrollment":108},{"nctId":"NCT01358526","phase":"PHASE3","title":"Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2011-05","conditions":"Low Back Pain","enrollment":1095},{"nctId":"NCT02573922","phase":"PHASE4","title":"Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery","status":"COMPLETED","sponsor":"Kuopio University Hospital","startDate":"2012-05","conditions":"Constipation","enrollment":180},{"nctId":"NCT01014559","phase":"PHASE3","title":"Efficacy of Oxycodone/Naloxone(OXN), Versus Oxycodone (OXY), for the Reduction of Intensity of Opioid-induced Constipation in Pain Patients","status":"TERMINATED","sponsor":"Mundipharma SAS","startDate":"2010-02","conditions":"Constipation, Pain","enrollment":225},{"nctId":"NCT01427283","phase":"PHASE3","title":"A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2011-08","conditions":"Low Back Pain","enrollment":450},{"nctId":"NCT01427270","phase":"PHASE3","title":"Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2011-08","conditions":"Low Back Pain","enrollment":455},{"nctId":"NCT01439100","phase":"PHASE3","title":"A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2011-10","conditions":"Parkinson's Disease With Severe Pain","enrollment":172},{"nctId":"NCT01167127","phase":"PHASE3","title":"Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain","status":"COMPLETED","sponsor":"Mundipharma Pharmaceuticals B.V.","startDate":"2009-06","conditions":"Pain","enrollment":113},{"nctId":"NCT00944697","phase":"PHASE2","title":"A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2009-07","conditions":"Moderate to Severe Pain Due to Diabetic Polyneuropathy","enrollment":98},{"nctId":"NCT01083485","phase":"PHASE4","title":"OXN PR Compared to OXY PR in Subjects With Postoperative Pain After Knee Arthroplasty","status":"COMPLETED","sponsor":"Mundipharma Oy","startDate":"2010-03","conditions":"Post Operative Pain","enrollment":137},{"nctId":"NCT00784810","phase":"PHASE4","title":"A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis","status":"COMPLETED","sponsor":"Napp Pharmaceuticals Limited","startDate":"2009-02","conditions":"Osteoarthritis, Back Pain","enrollment":247}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Targin®"],"phase":"marketed","status":"active","brandName":"oxycodone naloxone tablet","genericName":"oxycodone naloxone tablet","companyName":"Mundipharma Research GmbH & Co KG","companyId":"mundipharma-research-gmbh-co-kg","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxycodone naloxone tablets are used to treat opioid-use disorder, chronic pain, withdrawal symptoms, low back pain, and severe chronic pain. They are a small molecule medication that works by binding to opioid receptors in the body.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}